Condition
Neuroblastoma, Recurrent, Refractory
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Recruiting2
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06872489Unknown
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
NCT06674265Phase 1RecruitingPrimary
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
NCT06751134Phase 1RecruitingPrimary
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
NCT02644460Phase 1Completed
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
Showing all 4 trials